Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Buy” from Analysts

Context Therapeutics Inc. (NASDAQ:CNTX) has earned a consensus recommendation of “Buy” from the seven analysts that are currently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $6.17.

CNTX has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Context Therapeutics in a research note on Friday, March 21st. JMP Securities began coverage on Context Therapeutics in a research note on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price target on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research report on Friday, March 21st. Finally, Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th.

Context Therapeutics Stock Down 11.1 %

Shares of NASDAQ:CNTX opened at $0.66 on Monday. The firm has a market cap of $58.77 million, a price-to-earnings ratio of -0.72 and a beta of 2.06. Context Therapeutics has a 12 month low of $0.64 and a 12 month high of $2.75. The company’s fifty day simple moving average is $0.83 and its 200 day simple moving average is $1.39.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. Research analysts expect that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CNTX. Shay Capital LLC acquired a new stake in Context Therapeutics during the fourth quarter worth about $52,000. MPM Bioimpact LLC bought a new stake in shares of Context Therapeutics during the fourth quarter worth $15,441,000. Millennium Management LLC increased its holdings in shares of Context Therapeutics by 24.2% during the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock worth $188,000 after buying an additional 34,835 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Context Therapeutics during the fourth quarter worth $31,000. Finally, Allostery Investments LP acquired a new stake in shares of Context Therapeutics during the 4th quarter valued at $998,000. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.